Pharmalicensing brings you advice, commentary and analysis from industry experts.
An online directory that gives up to date licensing opportunities as well as real-time information on the industry at the touch of a button…. Martha Clancy, Innocoll.
Drug delivery specialists Innocoll Inc has profiled with Pharmalicensing for almost two years and this year became one of the first clients to upgrade its subscription to the Managed Partnering Service.
The managed partnering service introduced by Pharmalicensing to offer more in-depth partnering support was introduced early in 2007. The service includes a professionally written profile, a dedicated partner search, respondent screening and prominent company placement on both the website and in the newsletters.
Innocoll first began profiling with Pharmalicensing after hearing about them from industry insiders and following a recommendation from a member of staff. Innocoll is a specialty pharmaceutical and drug delivery company committed to the research and manufacture of collagen-based technologies. During its time with Pharmalicensing, Innocoll has made many contacts and has also initiated several discussions with potential partners.
Nothing to lose
Martha Clancy, Communications Officer at Innocoll believes by subscribing to the service you have nothing to lose ‘You simply put your profile up, pool in the enquiries and follow up any promising enquiries with a conference call or meeting where possible’. Potential partnerships can then be explored and discussed. ‘We are continuously evolving and even if the contacts aren’t exactly suitable for us at a particular time, the future could bring different strategies and requirements, opening the gates once again and allowing us to go back to previous contacts. We would always keep any contacts made through Pharmalicensing on file.’
When questioned specifically about her thoughts on the Managed Partnering Service Martha said ‘I like the extra level of service that is offered and the new ideas that you suggest in order to raise our profile on the website i.e. banner adverts and front page features.’ Innocoll feel its profile is looked after well by the staff at Pharmalicensing.
Standing out
Martha finds that one of the key differences of Pharmalicensing is the weekly newsletter. The newsletter is a summary of the weeks newly updated licensing opportunities, needs, company profiles, press releases and events. ‘The newsletter is a quick way of finding out about the newest opportunities, it goes straight into your email and you can scan through it, it saves you searching yourself.’ Martha also finds the regular profile statistics updates useful to review the levels of interest their profile generates.
In a typical week, Martha who is responsible for the Pharmalicensing profile at Innocoll will log in two to three times to check up on the its status and any activities.
Innocoll has already taken full advantage of the new website developments at Pharmalicensing, namely the jobs area. Martha found that many job sites did not target scientifically qualified staff and that the new Pharmalicensing jobs area provided another avenue for recruiting and promoting the company’s profile to a specific target market. Innocoll also post a number of press releases almost on a monthly basis and find the press release up-load very quick and user friendly.
Without any hesitation Martha says she would recommend Pharmalicensing to any companies actively searching for partners and looking to elevate their profile.
To make any comments on this article, or to ask a question of the author, please contact the publisher. If you would like to submit an article, please contact the editors.
The opinions expressed in the articles published in this section do not necessarily reflect those of Pharmalicensing or UTEK Corporation. No actions including proposals to or agreements with other companies should be taken by any reader without obtaining specific business or legal advice. Neither the publisher nor the authors accept any liability for any actions or activities undertaken by any reader or other third party as a consequence of these articles or for any errors or omissions therein.